ClinicalTrials.gg
CompletedNCT01474369Updated Jul 3, 2013

Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

A Phase 3 interventional study of TAK-438 and TAK-438 in Non-erosive Gastroesophageal Reflux Disease, sponsored by Takeda. Completed at 52 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-07-03.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
827
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing vonoprazan in Gastroesophageal Reflux — 5 open to participants now, 5 under way, 1 of them phase 3. vonoprazan · Gastroesophageal Reflux.

Enrollment
Largest of 16
827 · median 118
Started
2011
the only one that year
Phase 3
3 of 16
1 open now
Registered
1st of 16
by date
Lead sponsor
3 of 16
Takeda

Among the 16 studies testing vonoprazan in Gastroesophageal Reflux, this one has the largest enrollment, is the only one that started in 2011, is one of 3 in phase 3, and was the 1st registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

5 of the 16 studies testing vonoprazan in Gastroesophageal Reflux are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing vonoprazan in Gastroesophageal Reflux, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the superiority of efficacy of TAK-438, once daily (QD), to placebo in patients with non-erosive gastroesophageal reflux disease.

03

Conditions studied

  • Non-erosive Gastroesophageal Reflux Disease

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with grade N or M in the modified LA classification system confirmed by endoscopy at initiation of the pre-observation period (VISIT 1).
  2. Participants with repeated acid reflux symptoms (heartburn or regurgitation) for 2 days or more in one week in the 3 weeks before initiation of initiation of the pre-observation period (VISIT 1).
  3. Participants with severity* of moderate or higher for acid reflux symptoms (heartburn or regurgitation) in the 3 weeks before initiation of the pre-observation period (VISIT 1)

    * Severity: No symptoms, very mild (symptoms present but often forgotten), mild (not so painful), moderate (rather painful), severe (painful) and very severe (painful enough to affect night time sleep or daily activities)

  4. Outpatients (hospitalization for testing possible)

Exclusion criteria

Exclusion Criteria:

  1. Participants with an esophagus-related complication [Barrett's esophagus (3 cm or more, LSBE), eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infections, esophageal stenosis, etc.], or a history of radiotherapy or cryotherapy of the esophagus, a caustic or physiochemical trauma (esophageal sclerotherapy, etc.). However, participants with Barrett's esophagus (less than 3 cm, SSBE) or Schatzki's ring (mucosal tissue ring around inferior esophageal sphincter) are allowed to be included.
  2. Participants who have received surgery or treatment affecting gastroesophageal reflux (cardioplasty, dilation of esophageal stenosis [excluding Schatzki's ring], etc.), or who have a history of surgery of stomach or duodenum (excluding removal of benign polyp under endoscopy)
  3. Participants who have acute upper gastrointestinal bleeding, gastric ulcers (mucosal defects associated with white coating) or duodenal ulcers (mucosal defect with white coating) within 30 days before initiation of the pre-observation period (VISIT 1) However, participants with gastric or duodenal erosions are allowed to be included.
  4. Participants with acute gastritis or acute exacerbation of chronic gastritis as a complication
  5. Participants with a previous or current history of the Zollinger-Ellison syndrome or other gastric acid hypersecretion disorders
  6. Participants with a history of chest pain due to heart disease or with chest pains suspected of being caused by heart disease within one year before initiation of the pre-observation period (VISIT 1)
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
827 participants (actual)

Study arms

  • Experimental
    TAK-438 10 mg QD

    Drug: TAK-438

  • Experimental
    TAK-438 20 mg QD

    Drug: TAK-438

  • Placebo comparator
    Placebo QD

    Drug: Placebo

Interventions

  • TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.

  • TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.

  • DrugPlacebo

    TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of symptom-free days of heartburn symptoms

    Heartburn symptoms will be collected by participant diaries.

    Time frame: Week 4

  2. Cumulative symptom improvement rate of heartburn symptoms

    Heartburn symptoms will be collected by participant diaries.

    Time frame: Week 4

  3. Severity of heartburn symptoms

    Heartburn symptoms will be collected by participant diaries.

    Time frame: Week 4

Secondary outcomes

  1. Heartburn symptoms stratified by response (improvement or non-improvement) at Week 2

    Heartburn symptoms will be collected by participant diaries. Percentage of symptom-free days, cumulative symptom improvement rate, and severity of heartburn symptoms are evaluation parameters.

    Time frame: Week 4

  2. Heartburn Symptoms Stratified by Baseline Endoscopic Findings (Grade N or M)

    Heartburn symptoms collected by participant diaries. Percentage of symptom-free days, cumulative symptom improvement rate and severity of heartburn symptoms=evaluation parameters. Participants with Non-Erosive Gastroesophageal Reflux Disease divided into Grade N (endoscopically normal) and M (minimal change) by modified Los Angeles Classification System. Grade definitions: Grade N (endoscopically normal), M (minimal change), A (Mucosal break \<5 mm) B (Mucosal break ≥5 mm) C (Mucosal break continuous between 2 or more folds and \<75% of circumference) and D (Mucosal break ≥75% of circumference).

    Time frame: Week 4

  3. Heartburn symptoms stratified by combination of response at Week 2 and baseline endoscopic findings (improvement and grade N, improvement and grade M, non-improvement and grade N, non-improvement and grade M.)

    Heartburn symptoms will be collected by participant diaries. Percentage of symptom-free days, cumulative symptom improvement rate, and severity of heartburn symptoms are evaluation parameters.

    Time frame: Week 4

07

Study locations

52 sites
  • Nagoya-shi, Aichi, Japan
  • Abiko-shi, Chiba, Japan
  • Kashiwa-shi, Chiba, Japan
  • Noda-shi, Chiba, Japan
  • Yachiyo-shi, Chiba, Japan
  • Saijo-shi, Ehime, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Itoshima-shi, Fukuoka, Japan
  • Kasuya-gun, Fukuoka, Japan
  • Onga-gun, Fukuoka, Japan
  • Kouriyama-shi, Fukushima, Japan
  • Gifu-shi, Gifu, Japan
  • Takayama-shi, Gifu, Japan
  • Annaka-shi, Gunma, Japan
  • Hiroshima-shi, Hiroshima, Japan
  • Asahikawa-shi, Hokkaido, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Amagasaki-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Nishinomiya-shi, Hyogo, Japan
  • Takarazuka-shi, Hyogo, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kochi-shi, Kochi, Japan
  • Suzaki-shi, Kochi, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Sendai-shi, Miyagi, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Oita-shi, Oita, Japan
  • Okayama-shi, Okayama, Japan
  • Osaka-shi, Osaka, Japan
  • Takatsuki-shi, Osaka, Japan
  • Saga-shi, Saga, Japan
  • Kumagaya-shi, Saitama, Japan
  • Saitama-shi, Saitama, Japan
  • Tokorozawa-shi, Saitama, Japan
  • Otawara-shi, Tochigi, Japan
  • Bunkyo-ku, Tokyo, Japan
  • Chiyoda-ku, Tokyo, Japan
  • Chuo-ku, Tokyo, Japan
  • Hachioji-shi, Tokyo, Japan
  • Kokubunji-shi, Tokyo, Japan
  • Nakano-ku, Tokyo, Japan
  • Oota-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Shibuya-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Shimonoseki-shi, Yamaguchi, Japan
  • Kofu-shi, Yamanashi, Japan
  • Turu-shi, Yamanashi, Japan
  • Yamagata-shi, Ymagata, Japan
08

References and documents

Publications

  • Kinoshita Y, Sakurai Y, Shiino M, Kudou K, Nishimura A, Miyagi T, Iwakiri K, Umegaki E, Ashida K. Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. Curr Ther Res Clin Exp. 2016 Dec 21;81-82:1-7. doi: 10.1016/j.curtheres.2016.12.001. eCollection 2016. PubMed 28119763 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Nov 18, 2011
Start
Dec 2011
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
Jul 3, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01474369
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Dec 2011
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Jul 3, 2013

Study contacts

Senior Manager
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion